Multicenter Registry for Patients With Childhood.Onset Craniopharyngioma, Xanthogranuloma, Cysts of Rathke's Pouch, Meningioma, Pituitary Adenoma, Arachnoid Cysts

Rekrutierend

NCT-Nummer:
NCT04158284

Studienbeginn:
Oktober 2019

Letztes Update:
07.03.2024

Wirkstoff:
-

Indikation (Clinical Trials):
Adenoma, Meningioma, Pituitary Neoplasms, Craniopharyngioma, Adamantinoma, Arachnoid Cysts

Geschlecht:
Alle

Altersgruppe:
Alle

Phase:
-

Sponsor:
Klinikum Oldenburg gGmbH

Collaborator:
German Society for Pediatric Oncology and Hematology GPOH gGmbH, Deutsche Gesellschaft für Kinderendokrinologie und Diabetologie (DGKED), Deutsche Gesellschaft für Endokrinologie (DGE), Arbeitsgemeinschaft Pädiatrische Radioonkologie (APRO), Deutschen Gesells

Kontakt

Hermann L Mueller, MD
Kontakt:
Phone: +49 441 403
Phone (ext.): 2013
E-Mail: mueller.hermann@klinikum-oldenburg.de» Kontaktdaten anzeigen

Svenja Boekhoff
Kontakt:
Phone: +49 441 403
Phone (ext.): 2072
E-Mail: boekhoff.svenja@klinikum-oldenburg.de» Kontaktdaten anzeigen

Studienlocations
(1 von 1)

Brustzentrum Klinikum Oldenburg
Rahel-Straus-Straße 10
26133 Oldenburg
DeutschlandRekrutierend» Google-Maps
Ansprechpartner:
Hermann L Mueller, MD
Phone: +49 441 403
Phone (ext.): 2013
E-Mail: mueller.hermann@klinikum-oldenburg.de

Svenja Boekhoff
Phone: +49 441 403
Phone (ext.): 2072
E-Mail: boekhoff.svenja@klinikum-oldenburg.de» Ansprechpartner anzeigen

Studien-Informationen

Brief Summary:

KRANIOPHARYNGEOM Registry 2019 will prospectively collect and descriptively analyse data on

diagnostics, treatment, and follow-up of patients with craniopharyngioma. In continuation of

preceding studies also patients with xanthogranuloma, meningioma, pituitary adenoma,

prolactinoma and cystic intracranial malformations will be registered.

Ein-/Ausschlusskriterien

Inclusion Criteria:

1. Diagnosed with craniopharyngioma for the first time

2. Age at diagnosis 18 years or less of age

3. Agreement from patient's parents or legal guardian as well as the patient

Exclusion Criteria:

1. Age at diagnosis over 18 years of age

2. Diagnosis different from craniopharyngioma

Studien-Rationale

Primary outcome:

1. Overall Survival (Time Frame - 3 years follow-up):
Overall survival as measured by Kaplan Meyer analyses

2. Progression-free Survival (PFS) (Time Frame - 3 years follow-up):
Progression-free survival as measured by Kaplan Meyer analyses

Secondary outcome:

1. Quality of life (QoL) (Time Frame - 3 years follow-up):
Domains of the PedQol instrument (questionnaire for assessment of health-related QoL in childhood cancer patients.

Quelle: ClinicalTrials.gov